Article | 2026 SARyV Meeting
HELIOS-3: Investigating Axpaxli for Diabetic Retinopathy
Peter K. Kaiser, MD, FASRS, discusses the phase 3 HELIOS-3 trial of AXPAXLI for diabetic retinopathy, which is enrolling patients in Argentina, the United States, and other countries.







